Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2015-2017

ABSTRACT

1. Subject: 10 patients : Chronic low back pain patients with lumbar intervertebral disc degeneration 2. Investigational Product : Autologous adipose derived mesenchymal stem cells plus hyaluronic acid derivatives (Tissuefill) 3. Time frame - 1 year Detailed Description 1. Purpose of the Clinical Study : To transplant autologous adipose derived mesenchymal stem cells with hyaluronic acid to patients with chronic low back pain caused by a degenerative lumbar disc to examine the procedure's safety and efficacy. 2. Phases and Design of the Clinical Study : This clinical study is a I/IIa phase single-group, open, investigator initiated trial. 3. Investigational Product : Autologous adipose derived mesenchymal stem cells separated from the subject (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial). The investigational product mixed with 1 mL of the concomitant drug Tissuefill (hyaluronic acid derivatives, Cha Meditech Co., Ltd.). 4. Inclusion Criteria 1. Males and female subjects aged 18 or over and less than 70. 2. Subjects who have experienced pain in the lower back or buttocks who have failed to respond to conservative therapies performed for a period of 3 months or longer. 3. Oswestry Disability Index of 30 % or higher. 4. Visual Analogue Scale of 4 or higher. 5. Subjects who have received a Magnetic Resonance Imaging (hereinafter referred to as MRI) assessment of grades 3 to 4 for Lumbar 1 - Sacral 1, according to the Pfirrmann grading system. 6. Subjects who are assessed to have a similar degree of pain as usual when a discogram is performed on the degenerative lumbar disc(s) identified by MRI, having one or two discs that cause the concordant pain. 7. Subjects who have signed the informed consent form for stem cell transplantation therapy. 5. Exclusion Criteria 1. Subjects with severe lumbar stenosis or herniated nucleus pulposus in the lumbar exhibiting symptoms of nerve compression and requiring surgery. 2. Subjects with spinal instability, spondylitis, or vertebral fractures 3. Patients with severe intervertebral disc degeneration that has resulted in a reduction of the disc height by ½ or more. 4. Subjects with severe osteoporosis (with an average T-score of -2.5 or below in the lumbar bone density test) 5. Patients who have received intra-discal procedures such as stem cell therapy or the injection of steroids into the disc or surgery such as discectomy on the disc on which the cell transplantation is planned to be performed. 6. Patients who have received a lumbar epidural steroid injection within a week prior to the cells transplantation. 7. Subjects who are hypersensitive to sodium hyaluronate. 8. Pregnant or breastfeeding women 9. Female patients with the possibility of pregnancy during the period of the clinical study who are not using a medically acceptable method of contraception. 10. Subjects with mental illness or a drug or alcohol addiction or subjects who are incapable of understanding the purpose and method of this clinical study. 11. Subjects who have participated in another clinical study in the 30 days prior to this study. 12. Subjects with a severe medical disease (hypertension unresponsive to drug treatment, diabetes unresponsive to drug treatment, hepatocirrhosis, renal failure, tumor) that can affect the outcome of this clinical study. 13. Subjects with any other clinically significant findings that renders the subject unsuitable for the clinical study, as judged by the investigator responsible for the clinical study. 6. Dosage and Administration : The autologous adipose derived mesenchymal stem cell as the investigational product (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill 1mL/syringe are supplied to the operating room. The investigational product and the Tissuefill (hyaluronic acid derivatives) are mixed and placed in a 22 G syringe. A single dosage of 2ⅹ10^7 autologous adipose derived mesenchymal stem cells per person is administered on 5 subjects, and a single dosage of 4ⅹ10^7 cells per person is administered on 5 subjects, injected into the center of the nucleus pulposus. 7. Primary Endpoint: Evaluation of Safety and Tolerability The transplantation will be considered to be safe and tolerable, in the absence of the following types of counterevidence. - Adverse events of grade 3 (NCI grading system) or above related to the cell products/ any evidence that the cells were contaminated by pollutants / any evidence that the cells exhibit tumorigenic potential 8. Secondary Endpoint 1. Change in the T2 MRI signal intensity of the nucleus pulposus in autologous adipose derived mesenchymal stem cells at 6 and 12 months after the transplantation compared to before the transplantation 2. Change in the VAS at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 3. Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 4. Change in the Short Form (SF)-36 at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 5. Assessment of the overall improvement in the Disc Height Index (hereinafter referred to as DHI) at 6 and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation More... »

URL

https://clinicaltrials.gov/show/NCT02338271

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "1. Subject: 10 patients : Chronic low back pain patients with lumbar intervertebral disc degeneration 2. Investigational Product : Autologous adipose derived mesenchymal stem cells plus hyaluronic acid derivatives (Tissuefill) 3. Time frame - 1 year\n\nDetailed Description\n1. Purpose of the Clinical Study : To transplant autologous adipose derived mesenchymal stem cells with hyaluronic acid to patients with chronic low back pain caused by a degenerative lumbar disc to examine the procedure's safety and efficacy. 2. Phases and Design of the Clinical Study : This clinical study is a I/IIa phase single-group, open, investigator initiated trial. 3. Investigational Product : Autologous adipose derived mesenchymal stem cells separated from the subject (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial). The investigational product mixed with 1 mL of the concomitant drug Tissuefill (hyaluronic acid derivatives, Cha Meditech Co., Ltd.). 4. Inclusion Criteria 1. Males and female subjects aged 18 or over and less than 70. 2. Subjects who have experienced pain in the lower back or buttocks who have failed to respond to conservative therapies performed for a period of 3 months or longer. 3. Oswestry Disability Index of 30 % or higher. 4. Visual Analogue Scale of 4 or higher. 5. Subjects who have received a Magnetic Resonance Imaging (hereinafter referred to as MRI) assessment of grades 3 to 4 for Lumbar 1 - Sacral 1, according to the Pfirrmann grading system. 6. Subjects who are assessed to have a similar degree of pain as usual when a discogram is performed on the degenerative lumbar disc(s) identified by MRI, having one or two discs that cause the concordant pain. 7. Subjects who have signed the informed consent form for stem cell transplantation therapy. 5. Exclusion Criteria 1. Subjects with severe lumbar stenosis or herniated nucleus pulposus in the lumbar exhibiting symptoms of nerve compression and requiring surgery. 2. Subjects with spinal instability, spondylitis, or vertebral fractures 3. Patients with severe intervertebral disc degeneration that has resulted in a reduction of the disc height by \u00bd or more. 4. Subjects with severe osteoporosis (with an average T-score of -2.5 or below in the lumbar bone density test) 5. Patients who have received intra-discal procedures such as stem cell therapy or the injection of steroids into the disc or surgery such as discectomy on the disc on which the cell transplantation is planned to be performed. 6. Patients who have received a lumbar epidural steroid injection within a week prior to the cells transplantation. 7. Subjects who are hypersensitive to sodium hyaluronate. 8. Pregnant or breastfeeding women 9. Female patients with the possibility of pregnancy during the period of the clinical study who are not using a medically acceptable method of contraception. 10. Subjects with mental illness or a drug or alcohol addiction or subjects who are incapable of understanding the purpose and method of this clinical study. 11. Subjects who have participated in another clinical study in the 30 days prior to this study. 12. Subjects with a severe medical disease (hypertension unresponsive to drug treatment, diabetes unresponsive to drug treatment, hepatocirrhosis, renal failure, tumor) that can affect the outcome of this clinical study. 13. Subjects with any other clinically significant findings that renders the subject unsuitable for the clinical study, as judged by the investigator responsible for the clinical study. 6. Dosage and Administration : The autologous adipose derived mesenchymal stem cell as the investigational product (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill 1mL/syringe are supplied to the operating room. The investigational product and the Tissuefill (hyaluronic acid derivatives) are mixed and placed in a 22 G syringe. A single dosage of 2\u217910^7 autologous adipose derived mesenchymal stem cells per person is administered on 5 subjects, and a single dosage of 4\u217910^7 cells per person is administered on 5 subjects, injected into the center of the nucleus pulposus. 7. Primary Endpoint: Evaluation of Safety and Tolerability The transplantation will be considered to be safe and tolerable, in the absence of the following types of counterevidence. - Adverse events of grade 3 (NCI grading system) or above related to the cell products/ any evidence that the cells were contaminated by pollutants / any evidence that the cells exhibit tumorigenic potential 8. Secondary Endpoint 1. Change in the T2 MRI signal intensity of the nucleus pulposus in autologous adipose derived mesenchymal stem cells at 6 and 12 months after the transplantation compared to before the transplantation 2. Change in the VAS at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 3. Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 4. Change in the Short Form (SF)-36 at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 5. Assessment of the overall improvement in the Disc Height Index (hereinafter referred to as DHI) at 6 and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation", 
    "endDate": "2017-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02338271", 
    "keywords": [
      "safety", 
      "efficacy study", 
      "adipose", 
      "stem cell", 
      "pain patient", 
      "Intervertebral Disc Degeneration", 
      "patient", 
      "chronic low back pain patient", 
      "degeneration", 
      "product", 
      "hyaluronic acid", 
      "time frame", 
      "clinical study", 
      "chronic low back pain", 
      "lumbar", 
      "method", 
      "efficacy", 
      "single group", 
      "Ml", 
      "drug", 
      "CHA", 
      "Ltd.", 
      "inclusion", 
      "male", 
      "female subject", 
      "pain", 
      "buttock", 
      "conservative therapy", 
      "period", 
      "disability", 
      "scale", 
      "Magnetic Resonance Imaging", 
      "MRI", 
      "assessment", 
      "grade 3", 
      "grading", 
      "similar degree", 
      "disk", 
      "consent form", 
      "cell transplantation therapy", 
      "exclusion", 
      "nucleus pulposus", 
      "symptom", 
      "nerve compression", 
      "General Surgery", 
      "instability", 
      "spondylitis", 
      "vertebral", 
      "reduction", 
      "height", 
      "severe osteoporosis", 
      "average", 
      "Bone Density", 
      "intra", 
      "stem cell therapy", 
      "injection", 
      "steroid", 
      "cell transplantation", 
      "woman", 
      "female patient", 
      "possibility", 
      "pregnancy", 
      "acceptable method", 
      "contraception", 
      "mental illness", 
      "Alcoholism", 
      "medical disease", 
      "hypertension", 
      "drug treatment", 
      "diabetes", 
      "Renal Insufficiency", 
      "Neoplasm", 
      "significant finding", 
      "dosage", 
      "Organization and Administration", 
      "room", 
      "GS", 
      "cell", 
      "primary endpoint", 
      "Evaluation Study as Topic", 
      "tolerability", 
      "transplantation", 
      "absence", 
      "adverse event", 
      "evidence", 
      "pollutant", 
      "endpoint", 
      "signal intensity", 
      "VA", 
      "short form", 
      "overall improvement"
    ], 
    "name": "Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02338271"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00018.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410886.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452398.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2015-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s13287-017-0710-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092687302", 
          "https://doi.org/10.1186/s13287-017-0710-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13287-017-0710-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092687302", 
          "https://doi.org/10.1186/s13287-017-0710-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02338271"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02338271'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02338271'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02338271'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02338271'


 

This table displays all metadata directly associated to this object as RDF triples.

116 TRIPLES      16 PREDICATES      108 URIs      100 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02338271 schema:about anzsrc-for:3053
2 schema:description 1. Subject: 10 patients : Chronic low back pain patients with lumbar intervertebral disc degeneration 2. Investigational Product : Autologous adipose derived mesenchymal stem cells plus hyaluronic acid derivatives (Tissuefill) 3. Time frame - 1 year Detailed Description 1. Purpose of the Clinical Study : To transplant autologous adipose derived mesenchymal stem cells with hyaluronic acid to patients with chronic low back pain caused by a degenerative lumbar disc to examine the procedure's safety and efficacy. 2. Phases and Design of the Clinical Study : This clinical study is a I/IIa phase single-group, open, investigator initiated trial. 3. Investigational Product : Autologous adipose derived mesenchymal stem cells separated from the subject (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial). The investigational product mixed with 1 mL of the concomitant drug Tissuefill (hyaluronic acid derivatives, Cha Meditech Co., Ltd.). 4. Inclusion Criteria 1. Males and female subjects aged 18 or over and less than 70. 2. Subjects who have experienced pain in the lower back or buttocks who have failed to respond to conservative therapies performed for a period of 3 months or longer. 3. Oswestry Disability Index of 30 % or higher. 4. Visual Analogue Scale of 4 or higher. 5. Subjects who have received a Magnetic Resonance Imaging (hereinafter referred to as MRI) assessment of grades 3 to 4 for Lumbar 1 - Sacral 1, according to the Pfirrmann grading system. 6. Subjects who are assessed to have a similar degree of pain as usual when a discogram is performed on the degenerative lumbar disc(s) identified by MRI, having one or two discs that cause the concordant pain. 7. Subjects who have signed the informed consent form for stem cell transplantation therapy. 5. Exclusion Criteria 1. Subjects with severe lumbar stenosis or herniated nucleus pulposus in the lumbar exhibiting symptoms of nerve compression and requiring surgery. 2. Subjects with spinal instability, spondylitis, or vertebral fractures 3. Patients with severe intervertebral disc degeneration that has resulted in a reduction of the disc height by ½ or more. 4. Subjects with severe osteoporosis (with an average T-score of -2.5 or below in the lumbar bone density test) 5. Patients who have received intra-discal procedures such as stem cell therapy or the injection of steroids into the disc or surgery such as discectomy on the disc on which the cell transplantation is planned to be performed. 6. Patients who have received a lumbar epidural steroid injection within a week prior to the cells transplantation. 7. Subjects who are hypersensitive to sodium hyaluronate. 8. Pregnant or breastfeeding women 9. Female patients with the possibility of pregnancy during the period of the clinical study who are not using a medically acceptable method of contraception. 10. Subjects with mental illness or a drug or alcohol addiction or subjects who are incapable of understanding the purpose and method of this clinical study. 11. Subjects who have participated in another clinical study in the 30 days prior to this study. 12. Subjects with a severe medical disease (hypertension unresponsive to drug treatment, diabetes unresponsive to drug treatment, hepatocirrhosis, renal failure, tumor) that can affect the outcome of this clinical study. 13. Subjects with any other clinically significant findings that renders the subject unsuitable for the clinical study, as judged by the investigator responsible for the clinical study. 6. Dosage and Administration : The autologous adipose derived mesenchymal stem cell as the investigational product (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill 1mL/syringe are supplied to the operating room. The investigational product and the Tissuefill (hyaluronic acid derivatives) are mixed and placed in a 22 G syringe. A single dosage of 2ⅹ10^7 autologous adipose derived mesenchymal stem cells per person is administered on 5 subjects, and a single dosage of 4ⅹ10^7 cells per person is administered on 5 subjects, injected into the center of the nucleus pulposus. 7. Primary Endpoint: Evaluation of Safety and Tolerability The transplantation will be considered to be safe and tolerable, in the absence of the following types of counterevidence. - Adverse events of grade 3 (NCI grading system) or above related to the cell products/ any evidence that the cells were contaminated by pollutants / any evidence that the cells exhibit tumorigenic potential 8. Secondary Endpoint 1. Change in the T2 MRI signal intensity of the nucleus pulposus in autologous adipose derived mesenchymal stem cells at 6 and 12 months after the transplantation compared to before the transplantation 2. Change in the VAS at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 3. Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 4. Change in the Short Form (SF)-36 at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation 5. Assessment of the overall improvement in the Disc Height Index (hereinafter referred to as DHI) at 6 and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
3 schema:endDate 2017-12-01T00:00:00Z
4 schema:keywords Alcoholism
5 Bone Density
6 CHA
7 Evaluation Study as Topic
8 GS
9 General Surgery
10 Intervertebral Disc Degeneration
11 Ltd.
12 MRI
13 Magnetic Resonance Imaging
14 Ml
15 Neoplasm
16 Organization and Administration
17 Renal Insufficiency
18 VA
19 absence
20 acceptable method
21 adipose
22 adverse event
23 assessment
24 average
25 buttock
26 cell
27 cell transplantation
28 cell transplantation therapy
29 chronic low back pain
30 chronic low back pain patient
31 clinical study
32 consent form
33 conservative therapy
34 contraception
35 degeneration
36 diabetes
37 disability
38 disk
39 dosage
40 drug
41 drug treatment
42 efficacy
43 efficacy study
44 endpoint
45 evidence
46 exclusion
47 female patient
48 female subject
49 grade 3
50 grading
51 height
52 hyaluronic acid
53 hypertension
54 inclusion
55 injection
56 instability
57 intra
58 lumbar
59 male
60 medical disease
61 mental illness
62 method
63 nerve compression
64 nucleus pulposus
65 overall improvement
66 pain
67 pain patient
68 patient
69 period
70 pollutant
71 possibility
72 pregnancy
73 primary endpoint
74 product
75 reduction
76 room
77 safety
78 scale
79 severe osteoporosis
80 short form
81 signal intensity
82 significant finding
83 similar degree
84 single group
85 spondylitis
86 stem cell
87 stem cell therapy
88 steroid
89 symptom
90 time frame
91 tolerability
92 transplantation
93 vertebral
94 woman
95 schema:name Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration
96 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02338271
97 schema:sdDatePublished 2019-03-07T15:25
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Nddcbb7814fd047f7b891beb3691c076b
100 schema:sponsor https://www.grid.ac/institutes/grid.410886.3
101 https://www.grid.ac/institutes/grid.452398.1
102 schema:startDate 2015-01-01T00:00:00Z
103 schema:subjectOf sg:pub.10.1186/s13287-017-0710-3
104 schema:url https://clinicaltrials.gov/show/NCT02338271
105 sgo:license sg:explorer/license/
106 sgo:sdDataset clinical_trials
107 rdf:type schema:MedicalStudy
108 Nddcbb7814fd047f7b891beb3691c076b schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
111 rdf:type schema:DefinedTerm
112 sg:pub.10.1186/s13287-017-0710-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092687302
113 https://doi.org/10.1186/s13287-017-0710-3
114 rdf:type schema:CreativeWork
115 https://www.grid.ac/institutes/grid.410886.3 schema:Organization
116 https://www.grid.ac/institutes/grid.452398.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...